Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 478 clinical trials
Featured trial
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms (LIMBER)

The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of INCB057643 as monotherapy or combination with ruxolitinib for participants with myelofibrosis and other myeloid neoplasms.

myelofibrosis
cell transplantation
  • 0 views
  • 24 Oct, 2022
  • 21 locations
Featured trial
A Study to Assess the Safety of BIIB122 Tablets and if it Can Slow the Worsening of Early-Stage Parkinson's Disease in Participants Between the Ages of 30 and 80 (LUMA)

question, researchers will use a questionnaire called the Movement Disorder Society-Unified Parkinson's Disease Rating Scale, also known as the MDS-UPDRS. Researchers will use the MDS-UPDRS to learn about

movement disorder
hoehn and yahr scale
  • 9 views
  • 17 Nov, 2022
  • 6 locations
Featured trial
A Phase 1/2, Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy in Participants With Anemia Due to Myelodysplastic Syndromes or Multiple Myeloma

This Phase 1/2, open-label, dose-finding study is intended to evaluate the safety and tolerability, PK, PD, and efficacy of INCB000928 administered as monotherapy in participants with MDS or MM

lenalidomide
chronic myelomonocytic leukaemia
multiple myeloma
hydroxyurea
anemia
  • 1 views
  • 21 Oct, 2022
  • 12 locations
Featured trial
A Study to Assess if BIIB122 Tablets Are Safe and Can Slow Worsening of Early-Stage Parkinson's Disease in Participants With Specific LRRK2 Genetic Variants Between the Ages of 30 and 80 Using the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (LIGHTHOUSE)

> To help answer this question, researchers will use a questionnaire called the Movement Disorder Society-Unified Parkinson's Disease Rating Scale, also known as the MDS-UPDRS. The MDS

depression
movement disorder
hoehn and yahr scale
motor symptoms
  • 1 views
  • 16 Nov, 2022
  • 2 locations
Featured trial
Study in Parkinson Disease of Exercise (SPARX3)

This study is a Phase 3 multi-site, randomized, evaluator-masked, study of endurance treadmill exercise on changes in the Movement Disorder Society-Unified Parkinson Disease Rating Scale (MDS

datscan
movement disorder
SPECT Scan
  • 169 views
  • 07 Oct, 2022
  • 26 locations
Featured trial
Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome (MDS)

  • 312 views
  • 08 Nov, 2020
  • 1 location
Featured trial
COMMANDS - Myelodysplastic Syndromes (MDS) - ACE536-MDS-002 - Australia  

) versus epoetin alfa for the treatment of anemia due to IPSS-R very low, low or intermediate risk MDS in ESA naïve subjects who require RBC transfusions. The study is divided into the Screening

cancer
erythropoietin
epoetin alfa
vasectomy
  • 16800 views
  • 22 Aug, 2022
  • 7 locations
Featured trial
COMMANDS - Myelodysplastic Syndromes (MDS) - ACE536-MDS-002 - US  

luspatercept (ACE-536) versus epoetin alfa for the treatment of anemia due to IPSS-R very low, low or intermediate risk MDS in ESA naïve subjects who require RBC transfusions.   The

cancer
erythropoietin
epoetin alfa
vasectomy
  • 54541 views
  • 22 Aug, 2022
  • 9 locations
Featured trial
COMMANDS - Myelodysplastic Syndromes (MDS) - ACE536-MDS-002 – Canada  

safety of luspatercept (ACE-536) versus epoetin alfa for the treatment of anemia due to IPSS-R very low, low or intermediate risk MDS in ESA naïve subjects who require RBC transfusions. &nbsp

epoetin alfa
  • 23120 views
  • 22 Aug, 2022
  • 10 locations
Featured trial
Celgene MDS-AML Registry Connect

Celgene MDS-AML Registry Connect

  • 78 views
  • 08 Nov, 2020
  • 1 location